MA38425A1 - Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 - Google Patents

Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1

Info

Publication number
MA38425A1
MA38425A1 MA38425A MA38425A MA38425A1 MA 38425 A1 MA38425 A1 MA 38425A1 MA 38425 A MA38425 A MA 38425A MA 38425 A MA38425 A MA 38425A MA 38425 A1 MA38425 A1 MA 38425A1
Authority
MA
Morocco
Prior art keywords
compounds
selective agonists
receptor
bicyclic compounds
diseases
Prior art date
Application number
MA38425A
Other languages
English (en)
Other versions
MA38425B1 (fr
Inventor
Marta Dabros
T G Murali Dhar
Hai Yun Xiao
Alaric J Dyckman
Eric J Chan
Daniel Richard Roberts
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA38425A1 publication Critical patent/MA38425A1/fr
Publication of MA38425B1 publication Critical patent/MA38425B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/665—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system
    • C07C49/67—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings a keto group being part of a condensed ring system having two rings, e.g. tetralones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne des composés de formule (i) et/ou un de leurs sels; dans laquelle r représente -oh ou -op(o)(oh)2. L'invention concerne également des méthodes d'utilisation de tels composés comme agonistes sélectifs pour le récepteur s1p1couplé à la protéine g, et des compositions pharmaceutiques comprenant de tels composés. Ces composés sont utiles dans le traitement, la prévention, ou le ralentissement de la progression de maladies ou de troubles dans des domaines thérapeutiques variés, tels que ceux des maladies auto-immunes et des maladies vasculaires.
MA38425A 2013-02-21 2014-02-21 Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 MA38425B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767531P 2013-02-21 2013-02-21
PCT/US2014/017534 WO2014130752A2 (fr) 2013-02-21 2014-02-21 Composés bicycliques

Publications (2)

Publication Number Publication Date
MA38425A1 true MA38425A1 (fr) 2017-12-29
MA38425B1 MA38425B1 (fr) 2019-03-29

Family

ID=50272738

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38425A MA38425B1 (fr) 2013-02-21 2014-02-21 Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1

Country Status (34)

Country Link
US (3) US9115054B2 (fr)
EP (1) EP2958888B1 (fr)
JP (1) JP6277210B2 (fr)
KR (1) KR102242265B1 (fr)
CN (1) CN105026362B (fr)
AR (1) AR094851A1 (fr)
AU (1) AU2014218883B2 (fr)
BR (1) BR112015019919A2 (fr)
CA (1) CA2902168C (fr)
CL (1) CL2015002358A1 (fr)
CY (1) CY1118641T1 (fr)
DK (1) DK2958888T3 (fr)
EA (1) EA025294B1 (fr)
ES (1) ES2613262T3 (fr)
HR (1) HRP20170247T1 (fr)
HU (1) HUE031626T2 (fr)
IL (1) IL240613B (fr)
LT (1) LT2958888T (fr)
MA (1) MA38425B1 (fr)
MX (1) MX2015010347A (fr)
MY (1) MY173990A (fr)
PE (1) PE20151746A1 (fr)
PH (1) PH12015501793A1 (fr)
PL (1) PL2958888T3 (fr)
PT (1) PT2958888T (fr)
RS (1) RS55703B1 (fr)
SG (1) SG11201506408TA (fr)
SI (1) SI2958888T1 (fr)
SM (2) SMT201700115T1 (fr)
TN (1) TN2015000356A1 (fr)
TW (1) TWI613182B (fr)
UY (1) UY35338A (fr)
WO (1) WO2014130752A2 (fr)
ZA (1) ZA201506965B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6617702B2 (ja) 2013-07-15 2019-12-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｆｔｙ７２０のアザサイクリック拘束アナログ
TWI689487B (zh) * 2014-08-20 2020-04-01 美商必治妥美雅史谷比公司 經取代雙環化合物
CN108366990B (zh) * 2015-09-24 2021-09-03 加利福尼亚大学董事会 合成的鞘脂类分子、药物、它们的合成方法及治疗方法
WO2018045149A1 (fr) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Composés hétérocycliques tricycliques substitués
WO2019032632A1 (fr) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Composés d'alkylphényle
WO2019032631A1 (fr) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Composés d'éther d'oxime
WO2021062168A1 (fr) * 2019-09-25 2021-04-01 The Regents Of The University Of California Molécules inspirees par des sphingolipides synthetiques ayant des groupes pendants heteroaromatiques cytotoxiques, leurs procédés de synthèse et méthodes de traitement
WO2025083549A1 (fr) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Méthodes et combinaisons d'inhibiteurs de la voie il-23 et de modulateurs de la voie de signalisation s1p pour le traitement de maladies auto-immunes

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
AU2003202994B2 (en) 2002-01-18 2007-11-22 Merck Sharp & Dohme Corp. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as Edg receptor agonists
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US20050070506A1 (en) 2002-01-18 2005-03-31 Doherty George A. Selective s1p1/edg1 receptor agonists
AU2003217764A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
EP1549640A4 (fr) 2002-06-17 2008-08-06 Merck & Co Inc 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates et 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates utilises en tant qu'agonistes du recepteur edg
WO2005000833A1 (fr) 2003-05-19 2005-01-06 Irm, Llc Composes immunosuppresseurs et compositions
CN1894225A (zh) 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2006047195A2 (fr) 2004-10-22 2006-05-04 Merck & Co., Inc. Carboxylates, sulfonates, phosphonates, phosphinates 2-(aryl)azacyclylmethyle et heterocycles utilises comme agonistes des recepteurs s1p
JP2008530135A (ja) 2005-02-14 2008-08-07 ユニバーシティ オブ バージニア パテント ファンデーション アミノ基およびフェニル基で置換されたシクロアルカンならびに５員の複素環を含むスフィンゴシン＝１−リン酸アゴニスト
CA2598365A1 (fr) 2005-02-18 2006-11-16 Innodia Inc. Analogues de 4-hydroxyisoleucine et leurs utilisations
US8802840B2 (en) 2005-03-08 2014-08-12 Biota Scientific Management Pty Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
DE602006003642D1 (en) 2005-03-23 2008-12-24 Actelion Pharmaceuticals Ltd Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten
EP1873153B1 (fr) 2005-04-22 2010-07-07 Daiichi Sankyo Company, Limited Derives d'acide 3-azetidinecarboxylique utiles en tant qu'immunosuppresseurs
EP1893591A1 (fr) 2005-06-08 2008-03-05 Novartis AG Oxadiazoles polycycliques ou soxazoles i et leur utilisation comme ligands recepteurs de s1p
CA2619101A1 (fr) 2005-08-23 2007-03-01 Irm Llc Composes immunosuppresseurs et compositions associees
BRPI0706365A2 (pt) 2006-01-06 2011-03-22 Sepracor Inc Cicloalquilaminas como inibidores da recaptação de monoamina
MX2008009579A (es) 2006-01-27 2008-09-25 Univ Virginia Metodo para el tratamiento de dolor neuropatico.
WO2007088450A2 (fr) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagoniste du récepteur h-3
TW200806633A (en) 2006-03-21 2008-02-01 Epix Pharm Inc S1P receptor modulating compounds and use thereof
EP2001472A2 (fr) 2006-03-23 2008-12-17 Merck and Co., Inc. Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
TWI382984B (zh) 2006-04-03 2013-01-21 Astellas Pharma Inc 雜環化合物
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
MX2009002234A (es) 2006-09-08 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-3-il como agentes inmunomoduladores.
CA2672727A1 (fr) * 2006-12-21 2008-07-03 Abbott Laboratories Composes d'agonistes et d'antagonistes des recepteurs de sphingosine-1-phosphate
CN101610674A (zh) * 2006-12-21 2009-12-23 艾博特公司 鞘氨醇-1-磷酸酯受体激动剂和拮抗剂化合物
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
MX2009008255A (es) 2007-02-02 2009-08-12 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos taar1.
NZ580454A (en) 2007-03-16 2011-05-27 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
CA2700917A1 (fr) 2007-11-01 2009-05-07 Actelion Pharmaceuticals Ltd Nouveaux derives de pyrimidine
GB0725105D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
US8153686B2 (en) 2008-04-01 2012-04-10 Theravance, Inc. Amino- and amido-aminotetralin derivatives and related compounds as mu opioid receptor antagonists
US9181182B2 (en) 2008-10-17 2015-11-10 Akaal Pharma Pty Ltd S1P receptors modulators
BRPI0923178A2 (pt) 2008-12-18 2016-02-16 Merck Serono Sa derivados heterocíclicos de oxadiazol fundidos úteis para o tratamento de esclerose múltipla
EP2202232A1 (fr) 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. Dérivés du 1,2,4-oxadiazole et leur application thérapeutique
EP2210890A1 (fr) 2009-01-19 2010-07-28 Almirall, S.A. Dérivés d'oxadiazoles en tant qu'agonistes du récepteur S1P1
WO2010085584A1 (fr) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Dérivés de pyrazole-1,2,4-oxadiazole en tant qu'agonistes de sphingosine-1-phosphate
WO2010085582A1 (fr) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Dérivés d'oxadiazole substitués comme agonistes de s1p dans le traitement de maladies auto-immunes et inflammatoires
JP2012515787A (ja) 2009-01-23 2012-07-12 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
CN102316862A (zh) 2009-02-10 2012-01-11 雅培制药有限公司 制备s1p受体激动剂或拮抗剂的方法
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
WO2011059784A1 (fr) 2009-10-29 2011-05-19 Bristol-Myers Squibb Company Composés hétérocycliques tricycliques
EP2560969B1 (fr) 2010-04-23 2015-08-12 Bristol-Myers Squibb Company Amides du 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-acide mandelique comme agonistes du sphingosin-1-phosphate 1 recepteur
CN102260177A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 丙二醇类衍生物、其制备方法和其药物组合物与用途
CN102260178A (zh) 2010-05-25 2011-11-30 中国医学科学院药物研究所 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途
EP2595969B1 (fr) 2010-07-20 2015-04-22 Bristol-Myers Squibb Company Composés 3-phényle-1,2,4-oxadiazoles substitués
WO2012040532A1 (fr) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Composés oxadiazoles substitués et leur utilisation en tant qu'agonistes du s1p1
WO2012061459A1 (fr) 2010-11-03 2012-05-10 Bristol-Myers Squibb Company Composés hétérocycliques utilisés comme agonistes de s1p1 pour le traitement de maladies auto-immunes et vasculaires
US9682078B2 (en) 2011-03-18 2017-06-20 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
WO2012147311A1 (fr) 2011-04-26 2012-11-01 パナソニック株式会社 Système de chauffage, et procédé de commande de système de chauffage
GB201107325D0 (en) * 2011-05-04 2011-06-15 Glaxosmithkline Llc Novel compounds
US9481659B2 (en) 2011-05-13 2016-11-01 Celgene International Ii Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
NZ703851A (en) 2012-07-27 2017-01-27 Biogen Ma Inc Compounds that are s1p modulating agents and/or atx modulating agents

Also Published As

Publication number Publication date
LT2958888T (lt) 2017-02-10
CY1118641T1 (el) 2017-07-12
TW201444786A (zh) 2014-12-01
PE20151746A1 (es) 2015-12-02
ZA201506965B (en) 2017-08-30
PL2958888T3 (pl) 2017-07-31
KR20150119352A (ko) 2015-10-23
JP6277210B2 (ja) 2018-02-07
MX2015010347A (es) 2015-11-16
EA201591409A1 (ru) 2015-12-30
DK2958888T3 (en) 2017-03-06
MA38425B1 (fr) 2019-03-29
AU2014218883B2 (en) 2017-05-11
WO2014130752A3 (fr) 2014-10-23
TWI613182B (zh) 2018-02-01
US20140235591A1 (en) 2014-08-21
KR102242265B1 (ko) 2021-04-19
SMT201700115B (it) 2017-03-08
EP2958888B1 (fr) 2016-11-23
CA2902168A1 (fr) 2014-08-28
CN105026362B (zh) 2017-07-14
SI2958888T1 (sl) 2017-01-31
US9115054B2 (en) 2015-08-25
PT2958888T (pt) 2017-02-03
US20150315128A1 (en) 2015-11-05
MY173990A (en) 2020-03-03
SMT201700115T1 (it) 2017-03-08
IL240613A0 (en) 2015-10-29
RS55703B1 (sr) 2017-07-31
JP2016513124A (ja) 2016-05-12
PH12015501793B1 (en) 2015-11-09
WO2014130752A2 (fr) 2014-08-28
UY35338A (es) 2014-08-29
AR094851A1 (es) 2015-09-02
IL240613B (en) 2018-06-28
HRP20170247T1 (hr) 2017-04-07
HUE031626T2 (en) 2017-07-28
TN2015000356A1 (en) 2017-01-03
US9359286B2 (en) 2016-06-07
HK1218111A1 (en) 2017-02-03
US20160251309A1 (en) 2016-09-01
CN105026362A (zh) 2015-11-04
CA2902168C (fr) 2019-01-08
EA025294B1 (ru) 2016-12-30
BR112015019919A2 (pt) 2017-07-18
EP2958888A2 (fr) 2015-12-30
PH12015501793A1 (en) 2015-11-09
ES2613262T3 (es) 2017-05-23
SG11201506408TA (en) 2015-09-29
AU2014218883A1 (en) 2015-10-15
US9487481B2 (en) 2016-11-08
CL2015002358A1 (es) 2016-02-26

Similar Documents

Publication Publication Date Title
MA38425A1 (fr) Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1
MA47043B1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA33419B1 (fr) Composés et compositions pour le traitement de maladies parasitaires
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA38398A1 (fr) Composés biaryle amides en tant qu'inhibiteurs de kinase
MA35036B1 (fr) Composés bis(fluoroalkyl)-1,4-benzodiazépinone
MA41988B1 (fr) Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA35268B1 (fr) 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39750B1 (fr) Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
EP2873419A4 (fr) Composition pharmaceutique comprenant de l'azathioprine en tant que principe actif pour la prévention ou le traitement de tumeurs du cerveau ou de glioblastomes résistants à témodal
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite
MA44144B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs